[SCHEDULE 13G/A] TENAX THERAPEUTICS, INC. Amended Passive Investment Disclosure
Tenax Therapeutics: ING stake cut to 0% ownership
Tenax Therapeutics, Inc. (TENX) received an amended Schedule 13G/A from ING Groep N.V. and ING Capital Markets LLC reporting that, as of September 11, 2026, they no longer beneficially own any shares of Tenax common stock.
Tenax Therapeutics, Inc. (TENX) received an amended Schedule 13G/A from ING Groep N.V. and ING Capital Markets LLC reporting that, as of September 11, 2026, they no longer beneficially own any shares of Tenax common stock. All reported voting and dispositive powers have been reduced to zero.
The ownership percentages are calculated against 37,423,917 shares of Tenax common stock outstanding as of July 28, 2026, as referenced from Tenax’s Quarterly Report for the period ended June 30, 2026.
Positive
None.
Negative
None.
Key Figures
Shares beneficially owned by reporting persons:0 sharesPercent of Tenax common stock class owned:0.00%Tenax common shares outstanding:37,423,917 shares+2 more
5 metrics
Shares beneficially owned by reporting persons0 sharesAs of September 11, 2026
Percent of Tenax common stock class owned0.00%As of September 11, 2026, based on shares outstanding July 28, 2026
Tenax common shares outstanding37,423,917 sharesAs of July 28, 2026, per Tenax Quarterly Report for period ended June 30, 2026
Sole voting power of reporting persons0 sharesAs of September 11, 2026
Shared dispositive power of reporting persons0 sharesAs of September 11, 2026
Key Terms
beneficially owned, Sole Voting Power, Shared Dispositive Power
3 terms
beneficially ownedfinancial
"As of September 11, 2026, none of the Reporting Persons beneficially owned any Common Stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Voting Powerfinancial
"5 | Sole Voting Power 0.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Shared Dispositive Powerfinancial
"7 | Sole Dispositive Power 0.00 8 | Shared Dispositive Power 0.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change in ownership does this Schedule 13G/A report for TENX?
It reports that ING Groep N.V. and ING Capital Markets LLC no longer beneficially own any shares of Tenax Therapeutics common stock as of September 11, 2026, and have zero voting and dispositive power over the shares.
How many Tenax Therapeutics (TENX) shares do the reporting persons now own?
As of September 11, 2026, the reporting persons state they beneficially own 0 shares of Tenax Therapeutics common stock, with no sole or shared voting or dispositive power over any shares.
What percentage of Tenax Therapeutics (TENX) does ING report owning in this filing?
The reporting persons state that, as of September 11, 2026, they beneficially own 0.00% of Tenax Therapeutics common stock, based on 37,423,917 shares outstanding as of July 28, 2026.
What share count of Tenax Therapeutics (TENX) is used to calculate ownership percentages?
Ownership percentages are based on 37,423,917 shares of Tenax Therapeutics common stock outstanding as of July 28, 2026, as referenced from Tenax’s Quarterly Report for the period ended June 30, 2026.
Who are the reporting persons in this Tenax Therapeutics (TENX) Schedule 13G/A?
The reporting persons are ING Groep N.V., organized in the Netherlands, and ING Capital Markets LLC, organized in Delaware. They jointly report no beneficial ownership of Tenax Therapeutics common stock in this amendment.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Tenax Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
88032L605
(CUSIP Number)
09/03/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
88032L605
1
Names of Reporting Persons
ING Groep N.V.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
NETHERLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
HC
Comment for Type of Reporting Person: * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
88032L605
1
Names of Reporting Persons
ING Capital Markets LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.00 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: * Based on the 37,423,917 shares of common stock of the issuer (the "Common Stock") as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Tenax Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517, USA
Item 2.
(a)
Name of person filing:
ING Groep, N.V.
ING Capital Markets LLC
(b)
Address or principal business office or, if none, residence:
ING Groep N.V.
PO Box 1800
Amsterdam, P7
1000 BV Amsterdam
ING Capital Markets LLC
1133 Avenue of the Americas
New York, NY 10036
USA
(c)
Citizenship:
ING Groep N.V. - The Netherlands
ING Capital Markets LLC - Delaware
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
88032L605
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of September 11, 2026, none of the Reporting Persons beneficially owned any Common Stock.
(b)
Percent of class:
As of September 11, 2026, none of the Reporting Persons beneficially owned any percentage of the Common Stock issued and outstanding as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
ING Groep N.V.
Signature:
/s/ Bianca Jennifer Dobrescu
Name/Title:
Bianca Jennifer Dobrescu/Authorized Representative
